Evidence map›Paper›PMID 30583324›Full record

ReviewSheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi2018

[Screening of nucleic acid aptamer of lung cancer cells based on cell exponential enrichment ligand system evolution and its application in tumor diagnosis and treatment].

Jinling Xu, Shiqi Liao, Caiping Tian, Lei Zhang, Meng Zhai, Congying Chen, Jinzhou Tang, Jiayu Zeng

Abstract readEnglish AbstractReview
In one paragraph

Review in Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinling XuDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Shiqi LiaoDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Caiping TianDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Lei ZhangDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Meng ZhaiDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Congying ChenDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Jinzhou TangDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.
Jiayu ZengDepartment of Biochemistry and Molecular Biology, College of Life Sciences of Northwest Normal University, Lanzhou 730070, P.R.China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid aptamer is an oligonucleotide sequence screened by the exponential enrichment ligand system evolution technology (SELEX). Previous studies have shown that nucleic acid aptamer has a good application prospect in tumor diagnosis and treatment. Therefore, we reviewed the selection and identification of nucleic acid aptamer of lung cancer cells in recent years, and discussed the effect of aptamer as targeting drugs and targeting vectors on the diagnosis of tumors, which provide a new idea for early diagnosis and treatment of tumor.

Indexed as

aptamerlung cancer cellssystematic evolution of ligands for cell exponential enrichment technologytumor diagnosis and treatment

Identifiers

PMID30583324
PMCPMC9935205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.